menu
    • menu
    [{"orgOrder":0,"company":"Shine-On BioMedical","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SOB100","moa":"HLA-G","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shine-On BioMedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shine-On BioMedical \/ China Medical University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Shine-On BioMedical \/ China Medical University Hospital"},{"orgOrder":0,"company":"Shine-On BioMedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SOA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shine-On BioMedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shine-On BioMedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shine-On BioMedical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Shine-On BioMedical

    Menu

    Shine-On BioMedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shine-On BioMedical

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Shine-On BioMedical

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOA101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of SOA101 Safety & Preliminary Efficacy in Adults with Advanced Solid Tumors

                            Details : SOA101 is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 09, 2025

                            Lead Product(s) : SOA101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shine-On BioMedical

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed

                            Shine-On BioMedical

                            Taiwan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SOB100

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : China Medical University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            World's First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials

                            Details : The novel platform, named SOB100, has completed preclinical studies and demonstrated promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma.

                            Product Name : SOB100

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 09, 2025

                            Lead Product(s) : SOB100

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : China Medical University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth